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Amniotic fluid embolism (AFE) is a rare but life-threatening maternal emergency caused by the entry of amniotic
fluid contents into the maternal circulation. The clinical manifestations of AFE are heterogeneous, leading to
misdiagnosis or treatment delay. Kanayama and colleagues distinguished the cardiopulmonary collapse type (or
classic type) from the disseminated intravascular coagulation (DIC) type of AFE on the basis of the presence of
uterine atony and DIC in the latter prior to cardiopulmonary failure. We report a case of DIC-type AFE successfully
treated by blood volume replacement and coagulation therapy. The patient was scheduled for elective cesarean
delivery because of a previous cesarean section and moyamoya disease. Delivery was uneventful, but massive
vaginal bleeding without clotting and ensuing hypovolemic shock occurred 4 h later. She was transferred to the
operating room for emergency laparotomy, but sustained a cardiac arrest. The patient was successfully resuscitated
and a hysterectomy performed. During surgery, the patient received fresh frozen plasma, platelets, fibrinogen, and
antithrombin concentrate. In cardiopulmonary collapse type AFE, cardiopulmonary resuscitation without delay is
important. In the present case of DIC-type AFE, however, early supplementation of clotting factors and platelets was
critical for patient survival.
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Amniotic fluid embolism (AFE), a severe maternal reac-
tion to amniotic fluid contents entering the circulation,
occurs in only 2–8 of every 100,000 deliveries [1, 2].
However, AFE has a high mortality of 21.6 % in the
United States and 24.3 % in Japan [3, 4]. The risk factors
associated with AFE include advanced maternal age, pla-
cental abnormalities, operative deliveries, eclampsia,
polyhydramnios, cervical lacerations, and uterine rupture
[5]. The three classic AFE symptoms are acute hypoxia,
severe hypotension or cardiac arrest, and coagulopathy,
which generally occur suddenly during labor (or preg-
nancy termination) or shortly after delivery [6]. However,
AFE has a wide spectrum of manifestations, and patients
do not always follow the classic clinical course. On the* Correspondence: yufune@r4.dion.ne.jp
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provided the original work is properly creditedbasis of this clinical heterogeneity, it was recently sug-
gested that AFE may involve disseminated intravascular
coagulation (DIC), uterine atony, and (or) cardiopulmo-
nary collapse [4]. We present a case of AFE with cardiac
arrest arising from DIC following elective cesarean
delivery.Case presentation
A 38-year-old woman (67.3 kg, 160 cm tall, and G3 P2)
with moyamoya disease was scheduled for a repeat
cesarean delivery. She gave us her history of frequent
transient ischemic attacks during hyperventilation asso-
ciated with moyamoya disease; therefore, a cesarean de-
livery under general anesthesia was planned to avoid
ischemic attack during labor. She was not taking any
herbal preparations or anticoagulants. Laboratory find-
ings on admission were as follows: normal electrocardio-
gram and chest X-ray, hemoglobin 10.7 g/dL, platelet
count 32.2 × 104/μL, fibrin degradation product (FDP)ticle distributed under the terms of the Creative Commons Attribution License
hich permits unrestricted use, distribution, and reproduction in any medium,
.
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urinary glucose or protein. At 38 weeks and 1 day of
gestation, cesarean delivery was performed under gen-
eral anesthesia without complications. The patient’s tra-
chea was extubated and returned to the obstetrics ward.
Four hours after cesarean delivery, vaginal hemorrhage
increased rapidly. The patient’s systolic arterial pressure
decreased to 80 mmHg and heart rate (HR) increased to
148 beats/min. Ultrasound imaging and computed tom-
ography (CT) revealed a large retrovesical hematoma.
The patient was transferred to the operating room for
emergency laparotomy, and general anesthesia was in-
duced. A few minutes after skin incision, airway pressure
increased suddenly, SpO2 declined gradually, arterial
blood pressure became undetectable, and HR was absent.
Immediate cardiopulmonary resuscitation was initiated.
Spontaneous circulation resumed after administration of
1 mg epinephrine, but additional bolus injections and con-
tinuous epinephrine infusion were required to maintain
spontaneous circulation. The uterus was atonic and swol-
len to the size of a person’s head. Although a B-Lynch
suture was attempted, atonic hemorrhage remained un-
controlled and the decision to perform hysterectomy was
made. A large amount of bloody fluid was obtained from
the surgical site, and the blood did not clot. Bleeding from
the nose, the oral cavity, and the tracheal tube was ob-
served. Coagulation tests, including those for FDP, D-dimer,
and fibrinogen, showed that fibrinogen had decreased to
<50 mg/dL. We administered 44 units of packed red bloodFig. 1 Intraoperative anesthetic course and the result of coagulation tests.
blood pressure, SpO2 peripheral capillary oxygen saturation (%), FDP fibrin dcells (PRBCs), 44 units of fresh frozen plasma (FFP), 55
units of platelets, 8 g of fibrinogen, and 3,000 international
units (IU) of antithrombin concentrate during the surgery
(In Japan, estimated volume per unit of blood products is
as follows: PRBCs 140 mL/unit, FFP 120 mL/unit, platelet
20 mL/unit). Intraoperative anesthetic course and the
result of coagulation tests are shown in Fig. 1. After
hemodynamic conditions stabilized, hemorrhage from the
nose, the oral cavity, and the tracheal tube gradually de-
creased, and the patient was transferred to the intensive
care unit (ICU) without extubation.
Computed tomography after surgery revealed pulmon-
ary embolism (PE) but no cerebral hemorrhage. Heparin
therapy was initiated to maintain activated partial throm-
boplastin time (APTT) within the therapeutic target
range of 50–70 s. Results of intraoperative maternal
serum analysis were as follows: zinc coproporphyrin-1
(Zn-CP1) of 4 pmol/mL (normal, <1.6 pmol/mL), sialyl-
Tn antigen (STN) 20.0 IU/mL (normal, <46 IU/mL),
compliment factor 3 (C3) 58 mg/dL (normal, 80–140 mg/
dL), C4 9 mg/dL (normal, 11–34 mg/dL), and interleukin-8
(IL-8) 405 pg/mL (normal, <20 pg/mL). Increased Zn-CP1
and IL-8 with decreased C3 and C4 strongly suggested
AFE [7].
The pathological findings from the uterus of this patient
are shown in Fig. 2. The amniotic fluid-derived ingredients
are not detected in the hematoxylin-eosin (HE) staining,
but Anti-Pan Cytokeratin (AE1/AE3) stains detected am-
niotic fluid-derived fetal keratin (Fig. 2a) and alcian blueHR heart rate (/min), SBP systolic blood pressure (mmHg), DBP diastolic
egradation products
Fig. 2 Histological sections of the uterus. a Acid mucopolysaccharidic matter was observed in uterine vessels (black arrow), Alcian blue staining, 20×.
b Immunohistochemically marked epithelial squames in uterine vessels (black arrows), Cytokeratin AE1/AE3 immunohistochemical staining, 20×
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and edematous changes are observed in the uterus.
Seven days after the surgery, the patient’s trachea was
extubated and discharged from the ICU. Anticoagulant
therapy was switched from heparin infusion to warfarin.
Eighteen days after surgery, she was discharged from the
hospital.
Discussion
Steiner and Lushbaugh (1941) first reported the cases of
eight women who died unexpectedly from “obstetric
shock” associated with fetal material in pulmonary ves-
sels [8]. They concluded that pulmonary embolism from
particulate matter in amniotic fluid was the most likely
cause of death. Since then, many investigators have tried
to clarify the pathophysiology of AFE, but the etiology
remains controversial. Recent studies suggest that, in
addition to mechanical obstruction of pulmonary vessels,
AFE can also result from a systemic inflammatory re-
sponse syndrome (SIRS), manifesting as anaphylaxis or
septic shock [2]. Thus, Clark suggests the term “anaphy-
lactoid syndrome of pregnancy” to better describe the
pathophysiology of AFE [6].
The clinical manifestations of AFE include sudden
hypoxia, severe hypotension (including cardiac arrest),Table 1 New classification of amniotic fluid embolism
Initial symptoms Time from symptom
onset to cardiac arr
Cardiopulmonary collapse
type (Classic type)
• Sudden dyspnea Very short









DIC disseminated intravascular coagulationand DIC. In the classic AFE type, acute dyspnea and de-
saturation appear during labor or shortly after delivery,
followed by cardiopulmonary collapse and coagulopathy.
However, we have observed many cases of forme fruste
AFE in which one or more components of this symptom
triad were minimal or absent. Kanayama et al. suggested
that AFE can be separated into cardiopulmonary col-
lapse and DIC types on the basis of clinical findings
(Table 1) [4, 7]. In their report, the autopsies of five car-
diopulmonary collapse-type patients revealed no remark-
able changes in the uteri, whereas examination of four
DIC-type patients showed amniotic components in all
uteri, suggesting that the reaction of amniotic compo-
nents to the uterus can cause uterine atony and DIC [7].
In typical DIC-type AFE, the patient shows uterine atony
followed by DIC prior to cardiopulmonary symptoms;
therefore, volume resuscitation and the supplementation
of platelets and clotting factors are essential to save such
patients.
To manage hemorrhage during surgery, transfusion of
PRBCs is recommended to maintain oxygen transport at
first, and coagulation tests and platelet count should be
obtained before administering FFP and platelets [9]. How-
ever, many AFE patients require immediate FFP and plate-







• Amniotic components in
uterus and/or uterine vessels
Volume resuscitation including
supplement of platelets and
clotting factors
• Thrombus in uterine vessels
• Intestinal edema in uterus
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AFE. The blood transfusion strategy for AFE patients is
thus similar to the massive transfusion protocol for
trauma patients, in which disruption of hemostasis occurs
because of dilution coagulopathy, inflammatory mediator
activation, hyperfibriolysis, thrombocytopenia, and meta-
bolic abnormalities [10]. In our case, we recognized that
vaginal bleeding without clotting was an early sign of
DIC-type AFE and promptly initiated transfusion of
PRBCs and FFP (1:1), platelets, fibrinogen, and antithrom-
bin concentrate.
The diagnosis of AFE is based primarily on clinical ob-
servation. In the past, the detection of fetal squamous
cells in the maternal pulmonary circulation was consid-
ered a definitive diagnostic finding of AFE. However, a
recent study detected fetal squamous cells in only 50 %
AFE patients during the aspiration of pulmonary artery
blood [6], whereas another report found that the pres-
ence of squamous cells in the maternal circulation was
not always associated with AFE [11]. Although there is
no gold standard diagnostic marker for AFE, we believe
that changes in a number of serum factors are strongly
indicative of AFE, including Zn-CP1, STN, C3, C4, and
IL-8. Meconium is rich in Zn-CP1 [12], and STN is a
sugar chain of the mucin-type glycoprotein that recog-
nizes mucin in the meconium/amniotic fluid [13]. We
thus propose that STN and Zn-CP1 in the maternal cir-
culation are suggestive of AFE [7]. Benson et al. reported
that C3 and C4 levels in AFE patients were significantly
lower than normal [14], suggesting that complement ac-
tivation has an important role in the pathophysiology of
AFE. Amniotic fluid components can also activate im-
mune cells associated with allergic reactions, which pro-
duce large amounts of bradykinin and inflammatory
cytokines such as IL-8 [7]. Recently, C1 estarase inhibi-
tor activity (C1INH) was suggested as a prognostic
marker of AFE [15]. In addition to serum factors, histo-
logical observation revealed edematous changes exist in
the uterine smooth muscle and amniotic fluid compo-
nents and fetal epithelial cells in the uterine vessels in
this patient are suggestive of DIC-type AFE [7].
In this particular case patient, the reasons for cardiac ar-
rest are unclear. The possibilities include superimposed
cardiopulmonary type AFE and pulmonary thrombo-
embolism. Although the patient showed no symptoms of
deep vein thrombosis (DVT) before cesarean delivery, pre-
operative D-dimer levels were elevated; hence, DVT is
possible. Interestingly, both serum FDP and D-dimer de-
creased promptly after administration of fibrinogen and
antithrombin concentrate. The onset of cardiac arrest was
more than 4 h after delivery, not sudden, and initial symp-
toms was massive bleeding without clotting, we consid-
ered cardiac arrest was due to hypovolemic shock. We
cannot entirely exclude the classic type of AFE as thecausation of cardiac arrest, although initial manifestation,
change of serum factors, and histological observations in
uterus are suggestive of DIC-type AFE. Appropriate treat-
ment for DIC at the right time might lead to her recovery
from DIC.Conclusions
In conclusion, we describe a case of DIC-type AFE. Un-
like cardiopulmonary type AFE, uterine atony and DIC
were the initial symptoms. Early diagnosis and prompt
administration of blood products, including clotting fac-
tors and platelets, are essential for patient recovery.Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for re-
view by the Editor-in-chief of this journal.
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